Dexcom Q2 Revenue Hits $1.3B, Raises Full-Year Guidance on Strong CGM Demand
DXCM sits 40% above its 52-week low of $54.11.
Summary
Dexcom delivered a strong Q2 with revenue of $1.308 billion, up 13% year-over-year, driven by 11% U.S. growth and 19% international growth. GAAP operating income surged to $318.3 million, a 590 basis point margin expansion to 24.3% of revenue, while non-GAAP EPS reached $0.70. Management raised full-year revenue guidance to $5.18-$5.25 billion and lifted margin targets across the board, signaling confidence in sustained demand for its CGM systems. The quarter also featured positive results from the CONNECT trial, showing clinically meaningful benefits for type 2 diabetes patients not on insulin, and the launch of a revamped Stelo app with AI-driven insights. This follows a series of positive developments, including FDA clearance for Stelo in children and a $1 billion buyback program announced in May. The raised guidance and margin expansion suggest operating leverage is kicking in, making the stock's reaction on tomorrow's open the key near-term catalyst.
At the time of this announcement, DXCM was trading at $75.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.8B. The 52-week trading range was $54.11 to $89.98. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: BusinessWire.